CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE  
OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
ANNEX 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE 
OF MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
The Member States should ensure that all conditions or restrictions with regard to the safe and 
effective use of the medicinal product described below are implemented: 
1. 
The Member States shall agree the details of a Patient Alert Card (PAC) with the MAH, who 
must provide this PAC directly to the pharmacy with each Ranexa shipment. The Pharmacist 
should be requested to distribute a PAC to each patient at the time Ranexa is dispensed. The PAC 
must include the following key messages: 
Health Care Professional information 
The PAC should include the following information for the healthcare professional information 
regarding Ranexa: 
•  To refer to the Ranexa SPC prior to prescribing any medications to the patient, as there are 
potential drug interactions which should be taken into consideration. 
•  Ranexa is contraindicated in patients taking: 
•  Potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, voriconazol, posaconazol, HIV 
protease inhibitors, clarithromycin, telithromycin, nefazodone) 
•  Class Ia (e.g. quinidine) or Class III (e.g. dofetilide, sotalol) antiarrhythmics other than 
Amiodarone 
•  A dose reduction of Ranexa may be needed in combination with: 
•  Moderate CYP3A4 inhibitors (e.g. diltiazem, erythromycin, fluconazole) 
•  P-gp inhibitors (e.g. ciclosporin, verapamil) 
•  Caution should be exercised when prescribing Ranexa to patients: 
•  Taking certain other drugs mentioned in the product information 
•  With certain other risk factors listed in the product information 
• 
Inform the patient about the potential for an interaction with other prescribed medicinal products 
and to contact his/her doctor in case of dizziness, nausea or vomiting. 
Patient information 
The PAC should include the following information for the patient: 
•  That the card should be shown to any doctor involved in their treatment 
•  That prior to Ranexa treatment the patient should tell their doctor if they have any of the 
following: 
•  Kidney problems 
•  Liver problems 
•  Have ever had an abnormal electrocardiogram (ECG) 
•  Is taking medications to treat epilepsy, bacterial or fungal infections, HIV infection, 
depression or heart rhythm disorders 
•  Is taking the herbal remedy St John’s Wort 
•  Is taking allergy medicines 
•  That during treatment with Ranexa the patient should: 
•  Not drink Grapefruit Juice 
•  Call their doctor if they feel dizzy or sick, become sick or experience any unexpected 
symptoms after starting Ranexa. 
•  To refer to the Ranexa package leaflet for more information. 
•  To ensure to take a list of all their other medicines with them at any visit to the health care 
professional. 
2 
 
 
 
 
 
 
 
 
 
